Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 57

Sort by

Sort Order Select

Journal Articles

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Revathi Raj, Ramya Uppuluri, MD, Venkateswaran Vellaichamy, MD, Nikila Ravichandran, MD, Kesavan Melarkode Ramanan, MD

Blood (2019) 134 (Supplement_1): 5866.

https://doi.org/10.1182/blood-2019-131539

Published: 2019

Journal Articles

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507

Adetola A. Kassim, MDMS, Mark C. Walters, MD, Mary Eapen, MBBS, MS, Brianne Allison, MS, Adam M. Mendizabal, MS, Robert A. Brodsky, MD, Michael R. DeBaun, MDMPH

Blood (2019) 134 (Supplement_1): 802.

https://doi.org/10.1182/blood-2019-126321

Published: 2019

Journal Articles

Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study

Eléonore Kaphan, Raphaele Germi, Martin Carre, Claude-Eric Bulabois, MD, Sebastien Bailly, Jean-Yves Cahn, MD, Anne Thiebaut-Bertrand

Blood (2018) 132 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2018-99-115321

Published: 2018

Journal Articles

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Ryan D. Cassaday, MD, Jonathan R. Fromm, MD PhD, Andrew J. Cowan, MD, Stephen D. Smith, MD, Edward N. Libby, III, MD, Mary Philip, MD PhD, Margaret E. Nartea, Christen N. Heye, ARNP, Sandra L. Kanan, ARNP, Sanaz Behnia, MD, Ajay K. Gopal, MD

Blood (2017) 130 (Supplement 1): 2806.

https://doi.org/10.1182/blood.V130.Suppl_1.2806.2806

Published: 2017

Journal Articles

Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

Ryan D Cassaday, MD, Jonathan Fromm, MD PhD, Andrew J. Cowan, MD, Edward N. Libby, III, MD, Mary Philip, MD PhD, Sanaz Behnia, MD, Margaret Nartea, Oliver Press, Ajay K Gopal, MD

Blood (2016) 128 (22): 1834.

https://doi.org/10.1182/blood.V128.22.1834.1834

Published: 2016

Journal Articles

a Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells

Guillermo J. Ruiz-Arguelles, MD FRCP (Glasg), MACP, Andrés A. León-Peña, MD, Mónica León-Gonzalez, MD, Ana Karen Núñez-Cortés, MD, Merari Starlight Torres-Priego, MD, Jocelyn Vargas-Espinosa, MD, Emilio Medina-Ceballos, MD, Alejandro Ruiz-Arguelles, MD, Manuel Alejandro Ruiz-Delgado, MBA, Rodrigo J Ruiz-Delgado, BA, Guillermo Ruiz-Reyes, MD, Manuel Priesca-Marin, MD, David Blumenkron-Marroquin, MD, Guillermo J Ruiz-Delgado, MD FACP

Blood (2016) 128 (22): 2262.

https://doi.org/10.1182/blood.V128.22.2262.2262

Published: 2016

Journal Articles

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Timothy E. Kubal, MD MBA, Christopher Rodriguez Salamanca, PA, Julio C Chavez, MD, Bijal D. Shah, MD, Rami S. Komrokji, MD, Viet Q. Ho, PharmD, RPh, BCOP, Jeffrey E Lancet, MD

Blood (2015) 126 (23): 5604.

https://doi.org/10.1182/blood.V126.23.5604.5604

Published: 2015

Journal Articles

Low-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As an Efficacious and Safe Peripheral Blood Stem Cell Mobilizing Regimen in Patients with Hematologic Malignancies

Arun Sendilnathan, MD, Jaskirat Singh Randhawa, MD, Changchun Xie, Rebecca Bolt, RN, Thomas Leemhuis, Nora Buzek, Kitty Tierney, Susan Pinkard, Saulius Girnius, MD, Stephen Medlin, DO, FACP

Blood (2015) 126 (23): 5438.

https://doi.org/10.1182/blood.V126.23.5438.5438

Published: 2015

Journal Articles

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Kyle L. Runckel, BS, Cory Mavis, MSc, Joseph Skitzki, Juan J Gu, PhD, Francisco J. Hernandez-Ilizaliturri, MD, Myron S. Czuczman, MD

Blood (2015) 126 (23): 590.

https://doi.org/10.1182/blood.V126.23.590.590

Published: 2015

Journal Articles

Continuous intravenous injection of Mesna can effectively prevent Hemorrhagic cystitis in hematopoietic stem cell transplantation and retain the Mesna's concentration in urine: 394 cases reported within 11 years

Blood (2014) 124 (21): 2483.

https://doi.org/10.1182/blood.V124.21.2483.2483

Published: 2014

Journal Articles

ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma

Yoshiharu Kusano, MD, Yasuhito Terui, MD PhD, Noriko Nishimura, MD PhD, Kyoko Ueda, MD, Gunji Tadahiro, MD, Hideaki Nitta, MD, Yuko Mishima, MD#12288;PhD, Masahiro Yokoyama, MD, Naoko Tsuyama, MD, Kengo Takeuchi, MD PhD, Kiyohiko Hatake, MD PhD

Blood (2014) 124 (21): 5432.

https://doi.org/10.1182/blood.V124.21.5432.5432

Published: 2014

Journal Articles

Haploidentical Hematopoietic Stem Cell Transplantation With Reduced Intensity Conditioning, T-Cell Replete Grafts and Post-Transplant Cyclophosphamide In Pediatrics

Adriana Seber, MD, Valeria Cortez Ginani, MD, Roseane Gouveia, MD, Victor Zecchin, MD, Daniele Porto Barros, RN, Adriane Ibanez, RN, Leticia Alves Ribeiro, RN, Olga Margareth Wanderley Oliveira Felix, MS, Mariane Pereira Diniz, Pharm, Antonio Sergio Petrilli, MD

Blood (2013) 122 (21): 5510.

https://doi.org/10.1182/blood.V122.21.5510.5510

Published: 2013

Journal Articles

Continuous Intravenous Injection Of Mesna Can Reduce Acute Hemorrhagic Cystitis Occurrence Rate In Hematopoietic Stem Cell Transplantation: 359 Allo-HSCT Cases Report

Blood (2013) 122 (21): 4556.

https://doi.org/10.1182/blood.V122.21.4556.4556

Published: 2013

Journal Articles

Sulfolane (a metabolite of busulfan) Levels Could Predict Occurrence Of Hemorrhagic Cystitis In Children Receiving Busulfan Based Myeloablative Conditioning Before Hematopoietic Stem Cell Transplantation

Chakradhara Rao S Uppugunduri, Mohamed Aziz Rezgui, Yves Theoret, Patricia Huezo Diaz, PhD, Anuj Kumar Tyagi, PHD, Samira Mezziani, Marie-France Vachon, Catherine Desjean, Michel Duval, MD, Henrique Bittencourt, MD, Maja Krajinovic, MD, PhD, Marc Ansari, MD

Blood (2013) 122 (21): 4574.

https://doi.org/10.1182/blood.V122.21.4574.4574

Published: 2013

Journal Articles

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

Sabine Furst, MD, Roberto Crocchiolo, MD PhD, Jean El-Cheikh, MD PhD, Catherine Faucher, MD, Claire Oudin, Angela Granata, Geoffroy Venton, Claude Lemarie, Diane Coso, MD, Reda Bouabdallah, MD, Anne Marie Stoppa, Norbert Vey, Christian Chabannon, MD, PhD, Didier Blaise, MD

Blood (2012) 120 (21): 3031.

https://doi.org/10.1182/blood.V120.21.3031.3031

Published: 2012

Journal Articles

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Catherine S. Diefenbach, MD, David Kaminetzky, MD, Shannon Andersen, MSN, NP, Jane Chin, NP, Barbara MacGregor-Cortelli, BSN, RN, OCN, Jasmine M Zain, MD

Blood (2012) 120 (21): 4863.

https://doi.org/10.1182/blood.V120.21.4863.4863

Published: 2012

Journal Articles

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Jose D Sandoval-Sus, MD, Peter J Hosein, MD, Deborah Goodman, BHSC, Alexandra Stefanovic, MD, Joseph D Rosenblatt, MD, Izidore S Lossos, MD

Blood (2012) 120 (21): 1622.

https://doi.org/10.1182/blood.V120.21.1622.1622

Published: 2012

Journal Articles

Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3 rd Line (2 nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Yong Park, Seh Jong Park, Seok Young Lee, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD, PhD, Chul Won Choi, MD, PhD, Byung Soo Kim

Blood (2011) 118 (21): 2685.

https://doi.org/10.1182/blood.V118.21.2685.2685

Published: 2011

Journal Articles

Continuous Intravenous Injection of Mesna Is Powerful in Preventing Acute Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation: 108 Cases report

Qian-li Jiang, M.D., Ph.D., Qi-Fa Liu, Jing SUN, Zhiping Fan, Hongsheng Zhou, Yang Zhang, Yan-yan Chai, Dan Xu, Qi Wei, Guo-pan Yu, Jie Zhao, Xiao-fang Li, Guan-nan Yu, Qin Huang, Fan-Yi Meng

Blood (2011) 118 (21): 3015.

https://doi.org/10.1182/blood.V118.21.3015.3015

Published: 2011

Journal Articles

Extended Use of Ciprofloxacin Markedly Decreases the Incidence of Severe BK Virus-Associated Hemorrhagic Cystitis In Allogeneic HSCT Recipients

Ashley N Miller, FNP, MPH, Ashley S Glode, PharmD, Kathy Hogan, PharmD, Christine Schaub, ANP, AOCN, Robert K Stuart, MD, Luciano J Costa, MD., PhD

Blood (2010) 116 (21): 2317.

https://doi.org/10.1182/blood.V116.21.2317.2317

Published: 2010

NARROW

Cost Effective Cardio Protective Intervention in Haploidentical Hematopoietic Stem Cell Transplantation in Children - a Study from a Tertiary Care Centre in India

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell Disease: BMT CTN Protocol 1507

Risk Factors of BK Virus Cystitis in Haematopoietic Stem Cell Transplantation-a Retrospective Monocentric Study

Radiographic and High-Throughput Sequencing (HTS)-Based Response Assessment after Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Updated Results of a Phase I/II Trial

Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial

a Feasibility Study of the Full Outpatient Conduction of Hematopoietic Transplants in Persons with Multiple Sclerosis Employing Autologous Non-Cryopreserved Peripheral Blood Stem Cells

Transition of Intensive Chemotherapy for Acute Lymphoblastic Leukemia (ALL) to the Outpatient Setting: Analysis of Safety and Cost Savings

Low-Dose Cyclophosphamide Plus Granulocyte Colony-Stimulating Factor As an Efficacious and Safe Peripheral Blood Stem Cell Mobilizing Regimen in Patients with Hematologic Malignancies

Targeting the X-Linked Inhibitor of Apoptosis Protein (XIAP) Can Promote Tumor Cell Death, and Increase the Cytotoxic Effects of Chemotherapy Agents in in Vitro and In Vivo Models of Rituximab-Resistant Lymphoma

Continuous intravenous injection of Mesna can effectively prevent Hemorrhagic cystitis in hematopoietic stem cell transplantation and retain the Mesna's concentration in urine: 394 cases reported within 11 years

ICE (Ifosfamide, carboplatin, and etoposide) Was the Best Salvage Regimen in Patients with Relapsed or Refractory Malignant Lymphoma

Haploidentical Hematopoietic Stem Cell Transplantation With Reduced Intensity Conditioning, T-Cell Replete Grafts and Post-Transplant Cyclophosphamide In Pediatrics

Continuous Intravenous Injection Of Mesna Can Reduce Acute Hemorrhagic Cystitis Occurrence Rate In Hematopoietic Stem Cell Transplantation: 359 Allo-HSCT Cases Report

Sulfolane (a metabolite of busulfan) Levels Could Predict Occurrence Of Hemorrhagic Cystitis In Children Receiving Busulfan Based Myeloablative Conditioning Before Hematopoietic Stem Cell Transplantation

LOW Tranplant Related Mortality and LOW GRAFT Rejection After Related Haploidentical STEM CELL Transplantation (HAPLO-SCT) Prepared with NON Myeloablative CONDITIONING REGIMEN (NMA) and Posttransplant Cyclophosphamide for Advanced Lymphoid Malignancies.

The Chemotherapy Regimen IVAC Is Highly Active for Multiply Relapsed and Refractory Hodgkin Lymphoma

Updated Analysis of a Prospective Phase II Trial of R-MACLO-IVAM Followed by Maintenance for Mantle Cell Lymphoma

Treatment Outcomes and Prognostic Factors of Ifosfamide, Etoposide, Cytarabine, Methotrexate, and Dexamethasone (IVAMdex) Regimen As 3 rd Line (2 nd salvage) Chemotherapy in Patients with Relapsed or Refractory Non-Hodgkin's Lymphoma

Continuous Intravenous Injection of Mesna Is Powerful in Preventing Acute Hemorrhagic Cystitis in Hematopoietic Stem Cell Transplantation: 108 Cases report

Extended Use of Ciprofloxacin Markedly Decreases the Incidence of Severe BK Virus-Associated Hemorrhagic Cystitis In Allogeneic HSCT Recipients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only